Synced daily from ClinicalTrials.gov via AACT. Last sync: .
10 Foralumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 9 indications (including Non-Active Secondary Progressive Multiple Sclerosis & Secondary Progressive Multiple Sclerosis) and 157 total planned enrollment. 4 Foralumab clinical trials are actively recruiting at 10 U.S. sites across 5 states. Most recent activity: NCT06868628 (Apr 2027).
Where to Participate: All Foralumab Trial Sites in the U.S. (10 sites across 5 states)
Every actively recruiting Foralumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
10 Foralumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 4 are actively recruiting participants. 1 is marked completed.
Are Foralumab clinical trials recruiting in 2026?
Yes — 4 Foralumab trials are actively recruiting in 2026, with 10 U.S. sites across 5 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Foralumab being studied for?
Foralumab is being studied for Non-Active Secondary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, COVID-19 Respiratory Infection, Covid19, Crohn's Disease and 12 more. The trials are grouped by indication on this page.
What phase is Foralumab in?
Foralumab clinical trials span 6 Phase 2, 3 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Foralumab clinical trials?
The lead sponsor across the most Foralumab trials is Tiziana Life Sciences LTD, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Foralumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.